BioNTech SE (VIE:BNTX)
Austria · Delayed Price · Currency is EUR 96.05
+0.15 (0.16%)
Last updated: Aug 28, 2026, 1:00 PM CET
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
€339,439
Profits / Employee
€216,011
Market Cap
22.10B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Strabag SE | 88,556 |
| Erste Group Bank AG | 55,231 |
| Voestalpine AG | 48,641 |
| Raiffeisen Bank International AG | 41,704 |
| Vienna Insurance Group AG | 32,706 |
| Andritz AG | 30,557 |
| Telekom Austria AG | 16,616 |
| OMV Aktiengesellschaft | 15,936 |
BioNTech SE News
- 14 hours ago - BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why - TipRanks
- 14 hours ago - Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital - TheFly
- 15 hours ago - mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley - TheFly
- 17 hours ago - BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters
- 17 hours ago - BioNTech drops 9% after ending Phase 2 colorectal cancer trial - TheFly
- 17 hours ago - BioNTech to terminate Phase 2 monotherapy trial of cevumeran - TheFly
- 1 day ago - US FDA approves updated COVID vaccines for 2026-27 season - Reuters
- 1 day ago - Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine - TheFly